Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.

Covid Vaccine Update: How Do the Moderna and Pfizer Coronavirus Vaccines Compare?

The biotech might have hit a near-term top. But its future remains as bright as ever.

Is Moderna Still a Compelling Growth Play?

Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.

Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU

Moderna has got some promising news on the coronavirus vaccine front.

What Gives Moderna's Coronavirus Vaccine an Edge?

Don't worry about mutated strains of the coronavirus, experts say — the leading vaccine candidates should protect you against every version of the virus they've seen. Moderna and Pfizer each announced this month that their coronavirus vaccines prevent COVID-19 — the former's is 94.5% effective, while the latter's is 90%. Both companies hope to get approval from the FDA in the coming weeks.

Pfizer's and Moderna's vaccines likely work for all existing coronavirus strains. Don't worry about mutations for now, scientists say.

In this close race, Moderna offers a key data point -- and a logistical advantage.

2 Reasons Why Moderna's Coronavirus Vaccine Candidate Just Took the Lead Away from Pfizer

Could Moderna Become the Biggest Vaccine Company in the World Within 4 Years?

Manufacturing sites, skilled personnel and temperature control — just some of the challenges facing vaccine makers now.

Moderna's vaccine maker identifies the 'big challenges' to mass producing the coronavirus vaccine

Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.

Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

Here we highlight some leveraged ETFs that were up more than 7% on the favorable update from Moderna's vaccine progress.

7 Leveraged ETFs Rallying on Moderna's Coronavirus Vaccine News

It???s been really a sweet November for the global economy and markets thanks to back-to-back release of upbeat coronavirus vaccine data from Moderna and Pfizer.

ETF Strategies to Play as Vaccine Hopes Firm With Moderna Data

On Monday, Moderna (NASDAQ: MRNA) stock rallied by over 10% after the company said that its Covid-19 vaccine – which is based on messenger RNA technology – was 94.5% effective based on preliminary data. Investors have good reason to be optimistic about Moderna for multiple reasons.

What The Covid Vaccine Means For Moderna Stock

Moderna Inc (NASDAQ: MRNA) reported Monday with strong interim late-stage results for mRNA-1273, its coronavirus vaccine candidate. Despite the positive development, one analyst at BMO Capital Markets issued a downgrade of Moderna on Tuesday.

Why This Moderna Analyst Downgraded Biopharma Despite Positive COVID-19 Vaccine News

Shares of Moderna Inc. dropped Tuesday, to pull back from the previous session's record close, after BMO Capital analyst George Farmer recommended "taking some profits" as prices have already priced in most of the positive news on the company's COVID-19 vaccine candidate.

The Ratings Game: Moderna stock drops after BMO analyst recommends taking profit

Just as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer Inc Chief Executive Albert Bourla called on his top vaccine scientists and laid out a clear mission:

How two companies sprinted ahead in extraordinary race for a COVID vaccine

Shares of Moderna Inc. were down 1.8% in premarket trading on Tuesday after it announced a new supply deal with the United Kingdom government for its experimental COVID-19 vaccine. Per the terms, Moderna will begin supplying the government with its vaccine candidate in March if it's approved by U.K. health regulators.

Moderna signs supply deal with U.K. for COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Medicines Agency begins rolling review of Moderna's mRNA vaccine candidate against COVID-19 (mRNA-1273).

European Medicines Agency Begins Rolling Review of Moderna's mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

BioNTech SE

Better Coronavirus Vaccine: Moderna's mRNA-1273 or Pfizer and BioNTech's BNT162b2?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement with United Kingdom government to supply mRNA vaccine against COVID-19 (mRNA-1273) if approved for use

Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

Johnson & Johnson

Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.

3 Stocks to Win Big as Race for Coronavirus Vaccine Heats Up

Today the stock price of Moderna Inc (NASDAQ: MRNA) increased 9.58%. And it received a price target of $166 by Piper Sandler.

MRNA Stock Price: $166 Target By Piper Sandler

"If we can do that we will be back to a normal state by the end of next year," Dr. Carlos del Rio of Emory University told CNBC.

Moderna trial investigator says vaccinating U.S. against Covid will be a 'major effort'

Moderna updated expectations for the shelf life of its vaccine that could make it more accessible at a greater number of sites.

New Shelf-Life Data for Moderna's Coronavirus Vaccine Gives It an Edge

Moderna Inc (NASDAQ: MRNA) announced Monday positive efficacy data from the first interim analysis of the Phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained an Underperform rating on Moderna.

Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

Zoom Video

Investors need to get used to this tug of war in the months ahead.

News for Moderna Stock (MRNA)